ArticleBioMed research international2018
Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data.
Shuo Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.